Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 15/20 | 0.77 |
| ▸ | JAK1 | P23458 | 13/20 | 0.77 |
| ▸ | JAK3 | P52333 | 6/20 | 0.77 |
| ▸ | TYK2 | P29597 | 5/20 | 0.77 |
| ▸ | RET | P07949 | 3/20 | 0.77 |
| ▸ | ROCK1 | Q13464 | 3/20 | 0.77 |
| ▸ | DAPK3 | O43293 | 2/20 | 0.77 |
| ▸ | PAK4 | O96013 | 2/20 | 0.77 |
| ▸ | ABL1 | P00519 | 2/20 | 0.77 |
| ▸ | LTK | P29376 | 2/20 | 0.77 |
| ▸ | CSNK1A1 | P48729 | 2/20 | 0.77 |
| ▸ | CLK2 | P49760 | 2/20 | 0.77 |
| ▸ | TNK2 | Q07912 | 2/20 | 0.77 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.77 |
| ▸ | IKBKE | Q14164 | 2/20 | 0.77 |
| ▸ | NTRK3 | Q16288 | 2/20 | 0.77 |
| ▸ | NTRK2 | Q16620 | 2/20 | 0.77 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.77 |
| ▸ | TAOK1 | Q7L7X3 | 2/20 | 0.77 |
| ▸ | CAMK1D | Q8IU85 | 2/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL100309 | 1.00 | JAK2 (0.77) | JAK2JAK1JAK3TYK2RET | |
| SCHEMBL101864 | 0.92 | JAK2 (0.74) | JAK2JAK1JAK3TYK2RET | |
| Phosphoric Acid SCHEMBL27083980 | 0.91 | JAK2 (0.77) | JAK2JAK1JAK3TYK2RET | |
| Trifluoroacetic Acid SCHEMBL101747 | 0.91 | JAK2 (0.65) | JAK2JAK1JAK3TYK2RET | |
| SCHEMBL24767659 | 0.90 | JAK2 (0.72) | JAK2JAK1JAK3TYK2RET | |
| SCHEMBL18896326 | 0.89 | JAK2 (0.70) | JAK2JAK1JAK3TYK2RET | |
| SCHEMBL24053685 | 0.89 | JAK2 (0.75) | JAK2JAK1JAK3TYK2RET | |
| SCHEMBL10315658 | 0.89 | JAK2 (0.75) | JAK2JAK1JAK3TYK2RET | |
| SCHEMBL104692 | 0.89 | JAK2 (0.75) | JAK2JAK1JAK3TYK2RET | |
| SCHEMBL24505546 | 0.88 | JAK2 (0.74) | JAK2JAK1JAK3TYK2RET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240024490-A1 | BIFUNCTIONAL MOLECULES FOR SELECTIVE MODIFICATION OF TARGET SUBSTRATES | THE BROAD INSTITUTE, INC. | 2024-01-25 | — | — | US | disclosed |
| US-20230399331-A1 | SOLID FORMS OF JAK INHIBITOR AND PROCESS OF PREPARING THE SAME | INCYTE CORPORATION | 2023-12-14 | — | — | US | disclosed |
| US-20230192904-A1 | BIFUNCTIONAL CHIMERIC MOLECULES FOR LABELING OF KINASES WITH TARGET BINDING MOIETIES AND METHODS OF USE THEREOF | THE BROAD INSTITUTE, INC. | 2023-06-22 | — | — | US | disclosed |
| US-20230158037-A1 | SUBSTITUTED 4-AMINOISOINDOLINE-1,3-DIONE COMPOUNDS AND SECOND ACTIVE AGENTS FOR COMBINED USE | CELGENE CORPORATION | 2023-05-25 | — | — | US | disclosed |
| EP-3183252-B1 | OXALATE SALT OF RUXOLITINIB | RATIOPHARM GMBH (DE) | 2021-05-12 | — | — | EP | disclosed |
| US-10973913-B2 | JAK inhibitors and uses thereof | WASHINGTON UNIVERSITY (US) | 2021-04-13 | — | — | US | disclosed |
| US-20200282051-A1 | JAK INHIBITORS AND USES THEREOF | WASHINGTON UNIVERSITY (US) | 2020-09-10 | — | — | US | disclosed |
| US-20180185372-A1 | USE OF TREM-1 INHIBITORS FOR TREATMENT, ELIMINATION AND ERADICATION OF HIV-1 INFECTION | UNIV EMORY (US) | 2018-07-05 | — | — | US | disclosed |
| EP-3183253-B1 | SALT OF (R)-3-(4-(7H-PYRROLO [2,3-D]PYRIMIDIN-4-YL)-LH-PYRAZOL-L-YL)-3-CYCLOPENTYLPROPANENITRILE WITH BENZENESULFONIC ACID | RATIOPHARM GMBH (DE) | 2018-06-27 | — | — | EP | disclosed |
| US-9089574-B2 | Antiviral JAK inhibitors useful in treating or preventing retroviral and other viral infections | EMORY UNIVERSITY (US) | 2015-07-28 | — | — | US | disclosed |
| US-20140328793-A1 | ANTIVIRAL JAK INHIBITORS USEFUL IN TREATING OR PREVENTING RETROVIRAL AND OTHER VIRAL INFECTIONS | EMORY UNIVERSITY (US) | 2014-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140328793-A1 | ANTIVIRAL JAK INHIBITORS USEFUL IN TREATING OR PREVENTING RETROVIRAL AND OTHER VIRAL INFECTIONS | JAK1, JAK3, PNP | JAK2 4/4885JAK1 1/4885JAK3 2/4885 |
| US-20230399331-A1 | SOLID FORMS OF JAK INHIBITOR AND PROCESS OF PREPARING THE SAME | JAK1, JAK2, JAK3 | JAK2 2/4885JAK1 1/4885JAK3 3/4885 |
| US-20230158037-A1 | SUBSTITUTED 4-AMINOISOINDOLINE-1,3-DIONE COMPOUNDS AND SECOND ACTIVE AGENTS FOR COMBINED USE | DOT1L, CARM1, EZH2 | JAK2 32/4885JAK1 152/4885JAK3 556/4885 |
| US-20240024490-A1 | BIFUNCTIONAL MOLECULES FOR SELECTIVE MODIFICATION OF TARGET SUBSTRATES | COASY, JMJD7, PTMS | JAK2 3883/4885JAK1 4134/4885JAK3 3981/4885 |
| US-10973913-B2 | JAK inhibitors and uses thereof | JAK2, JAK1, JAK3 | JAK2 1/4885JAK1 2/4885JAK3 3/4885 |
| US-20230192904-A1 | BIFUNCTIONAL CHIMERIC MOLECULES FOR LABELING OF KINASES WITH TARGET BINDING MOIETIES AND METHODS OF USE THEREOF | ERBB2, ACP1, TK1 | JAK2 407/4885JAK1 643/4885JAK3 752/4885 |
| US-20180185372-A1 | USE OF TREM-1 INHIBITORS FOR TREATMENT, ELIMINATION AND ERADICATION OF HIV-1 INFECTION | MERTK, PNP, HAVCR2 | JAK2 277/4885JAK1 6/4885JAK3 85/4885 |
| US-20200282051-A1 | JAK INHIBITORS AND USES THEREOF | JAK2, JAK1, JAK3 | JAK2 1/4885JAK1 2/4885JAK3 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.